{"id":"buprenorphine-methadone-sequence","safety":{"commonSideEffects":[{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Respiratory depression"},{"rate":null,"effect":"Withdrawal symptoms (during transition)"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine is a partial mu-opioid agonist with high receptor affinity and slow dissociation, making it suitable for induction and early maintenance. Methadone is a full mu-opioid agonist with longer half-life, used for sustained maintenance therapy. This sequence leverages buprenorphine's safety profile and lower overdose risk during induction, followed by methadone's sustained action for long-term opioid substitution therapy.","oneSentence":"A sequential treatment protocol using buprenorphine followed by methadone, both opioid agonists that bind to mu-opioid receptors to reduce withdrawal symptoms and cravings in opioid use disorder.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:10.580Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (induction and maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT00310934","phase":"PHASE4","title":"A Stepwise Strategy Utilizing Buprenorphine and Methadone","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2005-08","conditions":"Heroin Dependence","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"buprenorphine / methadone sequence","genericName":"buprenorphine / methadone sequence","companyName":"Karolinska University Hospital","companyId":"karolinska-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A sequential treatment protocol using buprenorphine followed by methadone, both opioid agonists that bind to mu-opioid receptors to reduce withdrawal symptoms and cravings in opioid use disorder. Used for Opioid use disorder (induction and maintenance treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}